An exploratory biomarker analysis from the SKYSCRAPER-04 study, which investigated the clinical activity of tiragolumab plus atezolizumab vs. atezolizumab alone in PD-L1 expressing cervical cancer, indicated that the low PD-L1 expression subgroup showed numerical improvements in PFS and OS in the combination treatment arm compared with the atezolizumab monotherapy arm. Here, CD274 is linked to cervical carcinoma.